Nantahala Capital Management LLC Has $887,000 Stock Holdings in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)

Nantahala Capital Management LLC lowered its position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 88.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 211,110 shares of the company’s stock after selling 1,688,890 shares during the quarter. Nantahala Capital Management LLC owned 7.24% of Kiora Pharmaceuticals worth $887,000 as of its most recent SEC filing.

Kiora Pharmaceuticals Stock Up 6.7 %

Shares of KPRX opened at $3.66 on Tuesday. Kiora Pharmaceuticals, Inc. has a twelve month low of $3.00 and a twelve month high of $8.98. The firm’s 50 day moving average price is $3.76 and its two-hundred day moving average price is $4.65.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.42. The company had revenue of $0.02 million during the quarter. On average, equities analysts forecast that Kiora Pharmaceuticals, Inc. will post 1.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

KPRX has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Kiora Pharmaceuticals in a report on Thursday, August 22nd. Maxim Group upgraded Kiora Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 13th.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.